New psoriasis treatments based upon a deeper understanding of the pathogenesis of psoriasis vulgaris and psoriatic arthritis: A personal appraisal of their use in practice

Journal of the American Academy of Dermatology

Volumn 49, Issue 2, 2003, Pages 351-356

  Callen, Jeffrey P ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIPSORIASIS AGENT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PSORALEN; RETINOID;

BLOOD TOXICITY; CLINICAL PRACTICE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LIVER TOXICITY; NEPHROTOXICITY; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PRIORITY JOURNAL; PSORIASIS; PUVA; REVIEW; RISK BENEFIT ANALYSIS; TERATOGENICITY;

EID: 0043134974     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/S0190-9622(03)01149-6     Document Type: Note

References (18)

1. Menter MA, guest editor. Psoriasis for the clinician: a new therapeutics era ("the Biologics") beckons. J Am Acad Dermatol 2003;49(Suppl 2):S39-142.
2. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
3. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70.
4. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
5. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 2001;45:953-6.
6. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-80.
7. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000;27:2041-4.
8. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7.
9. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
10. Elewski BE. Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol 2002;47:796-7.
11. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN, Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821-33.
12. Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol 2002;138:686-8.
13. Gottleib AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002;138:591-600.
14. Gordon KB, Koo JYM, Feldman SR, Menter A, Krueger G. Definitions of measures of effect duration for psoriasis treatments. Psoriasis Forum 2002;8:1-5, 4.
15. Callis KP, Chadha A, Vaishnaw A, Krueger GG. Reductions of CD45RO+ effector T-lymphocyte is not observed in the treatment of psoriasis with methotrexate. J Invest Dermatol 2002;119:244(abstract 220).
16. Gottlieb AB, Papp KA, Lynde CW, Carey W, Powers J.: Subcutaneous efalizumab (anti-CD11a) is effective in the treatment of moderate to severe plaque psoriasis: pooled results of 2 phase III clinical trials. Poster presented at: 60th Annual Meeting of the American Academy of Dermatology; February 22-27, 2002; New Orleans, LA.
17. Abelson R. Drug sales bring huge profits, and scrutiny, to cancer doctors. New York Times. January 26, 2003;sect 1:1.
18. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003;120:211-6.